Wireless Implantable Intraocular Pressure Sensor System

无线植入式眼压传感器系统

• 批准号: 7215301
• 负责人: Lawrence Wan
• 金额: $ 41.91万
• 依托单位: BIOMEMS, LLC
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-05-01 至 2009-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7215301
• 关键词: Acceleration; Acids; Address; Affect; Animals; Artificial cardiac pacemaker; Atmospheric Pressure; Biocompatible; Biocompatible Coated Materials; Biocompatible Materials; Bite; Blindness; Budgets; Calibration; Cannulas; Cardiac; Cataract; Characteristics; Charge; Chemicals; Clinical; Clinical Data; Code; Communication; Communities; Compatible; Computer Simulation; Computer software; Consumption; Contact Lenses; Critiques; Custom; Data; Dental Implants; Deposition; Depth; Development; Devices; Diabetic Retinopathy; Diagnosis; Dimensions; Disease; Disease Management; Drainage procedure; Drug Delivery Systems; Electronics; Encapsulated; Engineering; Ensure; Equipment; Evaluation; Eye; Eye diseases; Failure; Fatty acid glycerol esters; Frequencies; Funding; Gases; Glaucoma; Glean; Goals; Grant; Hand; Healthcare; Heart Atrium; Heating; Hour; Human; Implant; Individual; Industry; Insulin Infusion Systems; International; Intraocular lens implant device; Intraocular pressure test; Invasive; Lead; Left; Letters; Life; Life Style; Link; Location; Longevity; Macular degeneration; Measurement; Measures; Medical; Membrane; Methodology; Methods; Miniaturization; Mission; Modeling; Modification; Monitor; National Eye Institute; Noise; Numbers; Operative Surgical Procedures; Orthopedics; Output; Outsourcing; Pain; Patients; Pattern; Performance; Permeability; Personal Satisfaction; Pharmaceutical Preparations; Pharmacotherapy; Phase; Physicians; Physiologic Intraocular Pressure; Placement; Play; Poly C; Polymers; Population; Positioning Attribute; Process; Proteins; Purpose; Range; Reading; Relative (related person); Research; Research Methodology; Resistance; Resolution; Resources; Respiratory Diaphragm; Retina; Risk; Risk Factors; Role; Sclera; Signal Transduction; Silicon; Sleep; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Source; Standards of Weights and Measures; Stream; Surface; Surgeon; Syringes; System; Techniques; Technology; Teflon; Temperature; Testing; Therapeutic; Time; Tissues; Titrations; United States Food and Drug Administration; Vacuum; Validation; Walking; Water; Wireless Technology; attenuation; base; biocompatible polymer; biomaterial compatibility; body system; bone; commercial application; concept; day; density; design; digital; driving force; evaluation/testing; implantable device; implantation; improved; information gathering; manufacturing process; medical specialties; meter; miniaturize; monomer; nerve supply; particle; parylene; parylene C; performance tests; pressure; prevent; prototype; remediation; research and development; response; sensor; simulation; size; software development; success; technological innovation; three-dimensional modeling; tonometry; tool; transmission process; vapor; vibration; voltage

DESCRIPTION (provided by applicant): This research will assess the technical feasibility of developing a new and unique miniature ophthalmic intraocular pressure (IOP) sensor, to be retrofitted into the cannula of a conventional Glaucoma Drainage Device (GDD) and surgically implanted under the sclera for the purpose of continuous measurement and transmission of these IOP readings to a remote receiver. Current technology does not allow for real-time, continuous monitoring of IOP (24/7, diurnal and nocturnal readings). The long-term objective of this project is to enable physicians to study, diagnose and more clearly understand the response mechanism relating to IOP that can lead to more effective development and titration of glaucoma medications or other timely therapeutic options. Elevated and fluctuating IOP over a 24/7 period is an independent and proven risk factor for eye damage in the short term and glaucoma progressions in the long term, which if left unchecked or unmanaged could lead to blindness. This Phase II research is dedicated to developing technologies that assist physicians to more effectively treat the glaucoma patient. This is inline with the mission of the National Eye Institute. Under Phase II, specific aims include system microminiaturization, packaging and biocompatibility. Research and development will specifically involve designing, fabricating, and integrating various MEMS and ASIC chips into a unitized singular micro scale chip to perform a number of systems activities (i.e. power transfer [RF-ID], chip interrogation, IOP data capture and storage, wireless data transfer, remediation, resolution, etc.) involving methods researched and determined in the successful portion of Phase I. These sequential methods include design input, product development, product integration (MEMS sensor, ASIC & biocompatible materials) and product validation and testing. In conclusion, with this telemetric IOP sensing technology, physicians will be able to measure the effects that medications and life-style factors have on the IOP of their patients in a real- time and continuous model.

描述（由申请人提供）：本研究将评估开发一种新型独特的微型眼科眼内压（IOP）传感器的技术可行性，该传感器将被改装到传统青光眼引流装置（GDD）的套管中，并通过手术植入巩膜下，以连续测量这些IOP读数并将其传输到远程接收器。当前技术不允许实时、连续监测IOP（24/7、昼夜读数）。该项目的长期目标是使医生能够研究、诊断和更清楚地了解与IOP相关的反应机制，从而更有效地开发和滴定青光眼药物或其他及时的治疗方案。在24/7的时间段内，IOP升高和波动是短期内眼损伤和长期青光眼进展的独立且经证实的风险因素，如果不加控制或不加管理，可能导致失明。这项II期研究致力于开发技术，帮助医生更有效地治疗青光眼患者。这符合国家眼科研究所的使命。在第二阶段，具体目标包括系统微型化、包装和生物相容性。研究和开发将具体涉及设计，制造和集成各种MEMS和ASIC芯片到一个单元化的单一微尺度芯片中，以执行许多系统活动（即功率传输[RF-ID]，芯片询问，IOP数据捕获和存储，无线数据传输，补救，解决方案等）。包括在第一阶段的成功部分中研究和确定的方法。这些顺序方法包括设计输入、产品开发、产品集成（MEMS传感器、ASIC和生物相容性材料）以及产品验证和测试。总之，通过这种遥测IOP传感技术，医生将能够在真实的时间和连续模型中测量药物和生活方式因素对其患者IOP的影响。